این سایت در حال حاضر پشتیبانی نمی شود و امکان دارد داده های نشریات بروز نباشند
Iranian Journal of Pediatric Hematology and Oncology، جلد ۴، شماره ۳، صفحات ۱۱۴-۱۱۷
عنوان فارسی
چکیده فارسی مقاله
کلیدواژه‌های فارسی مقاله
عنوان انگلیسی Side effects of hydroxyurea in patients with Thalassemia major and thalassemia intermedia and sickle cell anemia
چکیده انگلیسی مقاله Background Sickle hemoglobin is the most common abnormal hemoglobin in the United States. Hemoglobin S arises as a result of a single amino acid substitution (glutamic acid to valin at position 6 of the β-globine chain). The presence of fetal hemoglobin (HbF) plays a relatively protective role since a significant amount of HbF interferes with HbS polymerization, the pathogenesis mechanism of the vaso-occlusive symptoms that are the major contributor of the morbidity and mortality of this condition Thalassemia major and thalassemia intermedia have no specific molecular correlate but encompass a wide spectrum of clinical and laboratory abnormalities. Hydroxyurea (HU), an s-phase-specific and non-DNA-hypomethylating chemotherapeutic agents is capable of inducing HbF synthesis. Materials and Methods This study was done on 56 patients, 28 patients with sickle cell anemia (SCA) and 28 patients with intermediate or major β-thalassemia. Start dose of HU was 10 mg/kg per day and increased by 5 mg/kg per day every 4-6 weeks until toxicity or according to clinical response. Results The side effects were dermatologic in 39.28%, neurologic 23.2%, gastrointestinal 17.5% and hematologic 10.71% of patients. the statistical analysis didn't show significant relationship between variables such as history of blood transfusion, duration of HU treatment, age of start HU, age of diagnosis, dose of HU and ethnic with occurrence of HU adverse effects. Conclusion The HU therapy in our patients tolerated well and side effects were minor to moderate, benign and transient.
کلیدواژه‌های انگلیسی مقاله
نویسندگان مقاله a قاسمی | a ghasemi
assistant professor of pediatric hematology and oncology, faculty of medicine , mashhad university of medical sciences,

سازمان اصلی تایید شده: دانشگاه علوم پزشکی مشهد (Mashhad university of medical sciences)

b کیخایی | b keikhaei
associate professor of pediatric hematology and oncology, jondishapour university of medical sciences, ahvaz, research


r قدسی | r ghodsi
department of medicinal chemistry, school of pharmacy, mashhad university of medical sciences, mashhad iran

سازمان اصلی تایید شده: دانشگاه علوم پزشکی مشهد (Mashhad university of medical sciences)

نشانی اینترنتی http://ijpho.ssu.ac.ir/browse.php?a_code=A-10-70-22&slc_lang=en&sid=en
فایل مقاله فایلی برای مقاله ذخیره نشده است
کد مقاله (doi)
زبان مقاله منتشر شده en
موضوعات مقاله منتشر شده
نوع مقاله منتشر شده 1
برگشت به: صفحه اول پایگاه   |   نسخه مرتبط   |   نشریه مرتبط   |   فهرست نشریات